awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q37300812-F26CBC14-1083-482E-B62F-0CE37230B849
Q37300812-F26CBC14-1083-482E-B62F-0CE37230B849
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37300812-F26CBC14-1083-482E-B62F-0CE37230B849
Cost-effectiveness analysis of fesoterodine flexible dose in newly diagnosed patients with overactive bladder in routine clinical practice in Spain.
P2860
Q37300812-F26CBC14-1083-482E-B62F-0CE37230B849
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37300812-F26CBC14-1083-482E-B62F-0CE37230B849
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
d69eb4bebd5c9375d719cdadb1b717d885d8c582
P2860
Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain